It has been proposed that SchB can improve insomnia in rats through the 5-HT and GABA systems, including increasing hypothalamic levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA), 5-HT1AR content, GABA expression, GAD activity, and obviously upregulating GABAARα1 and GABAARγ2 protein expression; as well as decreasing Glu expression levels, significantly reducing GABA-T activity (Wang et al., 2020). The gene discussed is GAD1; the disease is insomnia measurement.